Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it ...
Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin–kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) ...
LDL cholesterol, often called “bad cholesterol,” can accumulate in the arteries, potentially leading to blood clots, stroke, or heart attack. HDL cholesterol, known as “good cholesterol,” helps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results